Veracyte, Inc. Veracyte, Inc.

Veracyte, Inc.

VCYT

Classifica tra le azioni #4414
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Prezzo delle azioni
$43.77
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$3.52B
Variazione (1 giorno)
1.51%
Variazione (1 anno)
19.43%
Paese
US
Scambia Veracyte, Inc. (VCYT)

Categoria

Healthcare
Storico del rendimento da dividendi per Veracyte, Inc. (VCYT)
Il rendimento da dividendi (TTM) di Veracyte, Inc. (simbolo azionario: VCYT) al 2023-12-31 è: 0.00%
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Veracyte, Inc. (VCYT) da 2011 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
Rendimenti da dividendi (TTM) di aziende simili o concorrenti